Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quoin PharmaceuticalsSTU:2EB0 19 3-Year ROIIC % is 2,254.17 as of Dec. 2025, which is 263% above its 10-year median of 620.19. GuruFocus rates STU:2EB0 with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 1,322 Biotechnology companies, Quoin Pharmaceuticals ranks better than 97.28% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Quoin Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 2,254.17%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Quoin Pharmaceuticals's 3-Year ROIIC % or its related term are showing as below:
STU:2EB0's 3-Year ROIIC % is ranked better than 97.28% of 1322
companies
in the Biotechnology industry
Industry Median: -4.82
vs STU:2EB0: 2254.17
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Quoin Pharmaceuticals 3-Year ROIIC % Related Terms
Quoin Pharmaceuticals 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Quoin Pharmaceuticals's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2EB0 vs RVPH, AIM, BRTX: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Quoin Pharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quoin Pharmaceuticals 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Quoin Pharmaceuticals's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Quoin Pharmaceuticals's 3-Year ROIIC % falls into.
Quoin Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -13.913 (Dec. 2025) - -8.74 (Dec. 2022) )
/
( 0.663 (Dec. 2025) - 1.027 (Dec. 2022) )
=
-5.173
/
-0.364
=
1,421.15%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Quoin Pharmaceuticals (STU:2EB0) has a 3-Year ROIIC % of 2,254.17 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Quoin Pharmaceuticals and its competitors. This is 263% above median its historical median of 620.19. Over the past decade, Quoin Pharmaceuticals' 3-Year ROIIC % has ranged from 462.00 to 2,254.17. According to the industry distribution chart, Quoin Pharmaceuticals ranks #36 out of 1322 companies in the Biotechnology industry, placing it in the top 2.7%.
Is Quoin Pharmaceuticals' 3-Year ROIIC % too high?
Quoin Pharmaceuticals' current 3-Year ROIIC % of 2,254.17 is 263% above median its 10-year median of 620.19. Over the past 10 years, this metric has ranged from a low of 462.00 to a high of 2,254.17. Based on the distribution chart, Quoin Pharmaceuticals ranks #36 out of 1322 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Quoin Pharmaceuticals has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Quoin Pharmaceuticals' 3-Year ROIIC % compare to RVPH and AIM?
According to the Biotechnology industry distribution chart, Quoin Pharmaceuticals ranks #36 out of 1322 companies for 3-Year ROIIC %. This places Quoin Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. Historically, Quoin Pharmaceuticals' own 3-Year ROIIC % has ranged from 462.00 to 2,254.17 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Quoin Pharmaceuticals and its competitors. Quoin Pharmaceuticals's current 3-Year ROIIC % is 2,254.17, which is 263% above median its own 10-year median of 620.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quoin Pharmaceuticals stock overvalued right now?
Quoin Pharmaceuticals (STU:2EB0) has a current 3-Year ROIIC % of 2,254.17. The current 3-Year ROIIC % is 2,254.17, which is 263% above median its 10-year median of 620.19. Quoin Pharmaceuticals' overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Quoin Pharmaceuticals (STU:2EB0), the current 3-Year ROIIC % is 2,254.17 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
19GF Score
Get the complete analysis for STU:2EB0
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2EB0 has been successfully added to your 
